BJA FY 2026 Harold Rogers Prescription Drug Monitoring Program | O BJA 2026 172675

FAQs: BJA FY 2026 Harold Rogers Prescription Drug Monitoring Program (PDMP)

What is this grant opportunity?

The BJA FY 2026 Harold Rogers Prescription Drug Monitoring Program (PDMP) is a discretionary grant opportunity from the U.S. Department of Justice, Bureau of Justice Assistance (BJA). It supports efforts to strengthen and modernize prescription drug monitoring programs so jurisdictions can better collect, manage, and analyze controlled-substance prescription data through a centralized, authorized database.

What is the primary purpose of the program?

The core purpose is to enhance the ability of regulatory agencies, law enforcement, and public health officials to use PDMP data to identify and respond to prescription drug diversion, misuse, and abuse, including issues involving opioids and other high-risk medications.

What is a PDMP in the context of this opportunity?

PDMPs are statewide or jurisdiction-wide systems that capture and organize information about the prescribing and dispensing of certain medications. Authorized users can review patterns of use and potential red flags to support prevention, early detection, oversight, and data-driven interventions.

Which federal agency is offering this funding?

The awarding agency is the U.S. Department of Justice, Bureau of Justice Assistance (BJA).

Is this a discretionary grant or a formula program?

This is a discretionary grant opportunity.

What is the official funding opportunity title?

The official title is "BJA FY 2026 Harold Rogers Prescription Drug Monitoring Program."

What is the funding opportunity number?

The funding opportunity number is O-BJA-2026-172675.

What is the CFDA number listed for this opportunity?

The CFDA number is 16.754.

What type of funding instrument is used?

The funding instrument is a grant.

What broad activity category does this opportunity fall under?

The broader activity category is Law, Justice and Legal Services.

Who is eligible to apply?

Eligible applicants include state governments, federally recognized Native American tribal governments, and other Native American tribal organizations.

What is the maximum award amount?

The NOFO lists an award ceiling of $2,000,000 per award.

When was this opportunity created?

The opportunity was created on August 13, 2026.

What is the application deadline?

The original application closing date is September 23, 2026.

What kinds of PDMP improvements does the program emphasize?

The opportunity emphasizes strengthening and modernizing PDMP capabilities, including improvements that increase PDMP usefulness, data quality, timeliness, analytics, and real-world impact.

Does the program support maintaining existing PDMP operations as well as enhancements?

Yes. The grant is intended to help jurisdictions maintain and enhance existing PDMP capabilities, while still allowing local decision-making based on each state or territory's laws, operational preferences, and policy choices.

What does the NOFO mean by "promising practices"?

A major theme of the Harold Rogers PDMP initiative is spreading and replicating promising practices. In practical terms, applicants are generally expected to build on what has been shown to work in improving PDMP performance and impact (such as data quality, timeliness, analytics, and use in real-world settings).

What is meant by integration and interoperability in this opportunity?

Integration and interoperability refer to connecting PDMP data more seamlessly with systems clinicians and pharmacists already use, such as health information exchanges (HIEs), electronic health records (EHRs), and pharmacy dispensing systems.

Why is workflow integration highlighted as important?

The opportunity describes workflow integration as a practical way to increase PDMP utilization and improve clinical decision-making at the point of care, because users can access relevant PDMP information within their existing tools.

Does the opportunity mention support for tribal entities and rural areas?

Yes. The NOFO highlights engagement with tribal entities and rural areas, noting these settings may have lower integration rates or face barriers such as limited infrastructure, staffing constraints, or vendor challenges.

How does strengthening PDMPs relate to public safety and public health goals?

The program frames PDMP strengthening as a way to reduce demand for misused prescription drugs and limit illegal trafficking and diversion, which can help disrupt cycles of addiction and violence. It also positions PDMP enhancement as a multi-sector strategy supporting prevention, early detection, and data-driven interventions.

Are PDMPs only intended for clinical use under this program?

No. While PDMPs are often associated with clinical decision support, the opportunity also notes PDMPs play a role in regulatory oversight and supporting appropriate, lawful investigative activities.

Who are the main intended users or beneficiaries of improved PDMP capability?

The program highlights benefits for regulatory agencies, law enforcement, and public health officials, and it also emphasizes access for clinicians and pharmacists through integration with EHRs, HIEs, and pharmacy dispensing systems.

Does the opportunity specify that the PDMP database is centralized and access is controlled?

Yes. The purpose statement describes collecting, managing, and analyzing data through a centralized, authorized database, indicating access is intended for authorized users.